Johnson & Johnson (JNJ) Gains from Sales and Divestitures (2010 - 2012)
Johnson & Johnson's (JNJ) quarterly Gains from Sales and Divestitures came in at $8.3 million in Q1 2012, up 31.81% year-on-year from $6.3 million in Q1 2011, and up 31.81% quarter-over-quarter from $6.3 million in Q1 2011.
Johnson & Johnson (JNJ) Gains from Sales and Divestitures (2010 - 2012) Analysis & Trends
Johnson & Johnson has disclosed Gains from Sales and Divestitures across 3 years of filings, most recently posting $8.3 million for Q1 2012.
- Gains from Sales and Divestitures for Q1 2012 came in at $8.3 million, up 31.81% year-over-year; the trailing twelve-month figure through Jan 2012 was $8.3 million (up 31.81% YoY), and the FY2012 annual result was $8.3 million, up 31.81% from the prior year.
- Gains from Sales and Divestitures came in at $8.3 million for Q1 2012 at Johnson & Johnson, up from $6.3 million in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $8.3 million in Q1 2012 to a low of $5.7 million in Q1 2010.
- The 3-year median for Gains from Sales and Divestitures is $6.3 million (2011), against an average of $6.8 million.
- Across the five-year window, Gains from Sales and Divestitures climbed 10.2% in 2011 and soared 31.81% in 2012, its largest moves.
- Johnson & Johnson's Gains from Sales and Divestitures stood at $5.7 million in 2010, then grew by 10.2% to $6.3 million in 2011, then soared by 31.81% to $8.3 million in 2012.
- The last three Gains from Sales and Divestitures figures came in at $8.3 million (Q1 2012), $6.3 million (Q1 2011), and $5.7 million (Q1 2010), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 1, 2012 | 8.30 Mn |
| Jan 1, 2012 | 8.30 Mn |
| Jan 2, 2011 | 6.30 Mn |
| Jan 2, 2011 | 6.30 Mn |
| Jan 3, 2010 | 5.71 Mn |
| Jan 3, 2010 | 5.71 Mn |